Pfizer, Inc. (NYSE:PFE) posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02, Morningstar.com reports. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. Pfizer updated its FY17 guidance to $2.54-2.60 EPS.
Shares of Pfizer (NYSE:PFE) traded down 0.85% during trading on Friday, reaching $32.67. The company’s stock had a trading volume of 15,490,145 shares. Pfizer has a 52 week low of $29.83 and a 52 week high of $35.38. The company has a market cap of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00. The stock’s 50 day moving average price is $33.30 and its 200 day moving average price is $33.38.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Asset Planning Services Ltd. raised its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the period. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the second quarter valued at $103,000. D. Scott Neal Inc. raised its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Finally, Orrstown Financial Services Inc. raised its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. 69.94% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have commented on the stock. Berenberg Bank reaffirmed a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a research note on Tuesday. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price objective on shares of Pfizer in a research note on Friday. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, UBS AG reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $37.61.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.